By Fineline Cube 
Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and lung cancer business unit, is set to leave the company, with his last working day scheduled for June 30.
Career Journey at AstraZeneca
Lai Minglong joined AstraZeneca in June 2017 and became vice president of AstraZeneca’s cardiovascular and metabolic business unit in China. In 2018, he was promoted to general manager of AstraZeneca China and concurrently served as head of the oncology business unit for AstraZeneca China.
Global Leadership Role
In December 2024, he transitioned to the global head of Dato-DXd and lung cancer business unit, reporting to Sunil Verma, senior vice president of global oncology. In this role, he led the global launch of Datroway, a TROP2 – targeting DXd antibody – drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo. He also spearheaded the strategic development of AstraZeneca’s global lung cancer business.
AstraZeneca’s Comments
AstraZeneca has expressed its gratitude for Mike La’s contributions to the company and wished him well in his future endeavors.-Fineline Info & Tech